Pfizer will not seek Emergency Use Authorization (EUA) for its COVID-19 vaccine (BNT162b2) until end of November
Pfizer posted letter explaining the vaccine must meet 3 key metrics before it will seek EUA: it must be effective in preventing COVID-19 in at least a majority of vaccinated patients, meet safety standards, and can be consistently manufactured while meeting QC standards.
Source:
Biospace Inc.